Related Experiment Video
Updated: Apr 5, 2026

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
Remodeling Amyloid Fibers: Baker's Yeast Shows Us the Way
Eva Asp1, Ming Proschitsky1, Rajaraman Krishnan1
1Neurophage Pharmaceuticals, 222 Third Street, Suite 3120, Cambridge, MA 02142, USA.
Abstract:
Proteopathies are a large and diverse group of human diseases that are caused by protein misfolding. Well-known examples of proteopathies are Alzheimer's and Parkinson's disease, which are both linked to amyloid fibril formation. In this issue of Chemistry & Biology, Castellano et al. (2015) describe the way to harness the power of a protein from baker's yeast, Hsp104, to disaggregate the fibrils.
Insights
Researchers harnessed a yeast protein, Hsp104, to break down amyloid fibrils. This protein disaggregation method offers potential therapeutic strategies for proteopathies like Alzheimer's and Parkinson's disease.
Area of Science:
- Biochemistry
- Molecular Biology
- Neuroscience
Background:
- Proteopathies are diseases caused by protein misfolding, including Alzheimer's and Parkinson's.
- Amyloid fibril formation is a common characteristic of these debilitating neurodegenerative diseases.
- Current treatments for proteopathies are limited, highlighting the need for novel therapeutic approaches.
Purpose of the Study:
- To investigate the potential of the yeast protein Hsp104 as a disaggregase for amyloid fibrils.
- To explore a novel strategy for combating protein misfolding diseases.
Main Methods:
- Utilizing Hsp104, a protein from baker's yeast, known for its protein disaggregation capabilities.
- Applying Hsp104 to disaggregate pre-formed amyloid fibrils associated with proteopathies.
Main Results:
- Demonstrated the efficacy of Hsp104 in breaking down amyloid fibrils.
- Showcased the potential of protein disaggregation as a therapeutic avenue for proteopathies.
Conclusions:
- Hsp104 can be harnessed to disaggregate disease-associated amyloid fibrils.
- This study presents a promising new approach for developing treatments for proteopathies.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils

